Skip to main
CVRX

CVRx (CVRX) Stock Forecast & Price Target

CVRx (CVRX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 0%
Sell 25%
Strong Sell 0%

Bulls say

CVRx is off to a strong start in 2026, with preliminary Q1 revenue and gross margin both exceeding expectations and guidance. The company has a solid balance sheet with significant cash and is well-positioned for continued rep productivity gains and growth through the BENEFIT-HF trial, which could expand its TAM by 3x. However, there is still a level of risk associated with the company's heavy dependence on a single product for revenue, limited long-term clinical data, and the potential for future losses and dilution.

Bears say

CVRx is a commercial-stage medical device company with a proprietary platform technology focused on treating cardiovascular diseases. While they have a strong revenue model and have announced positive updates, such as CMS Category B coverage for the BENEFIT-HF trial and the implementation of Category I CPT codes, the company is facing challenges with lower active account numbers and a decline in the small-cap med-tech comp group multiple. This, along with the potential for continued salesforce disruption, leads to a negative outlook on CVRx's stock as their growth may be limited in the near future.

CVRx (CVRX) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CVRx (CVRX) Forecast

Analysts have given CVRx (CVRX) a Buy based on their latest research and market trends.

According to 4 analysts, CVRx (CVRX) has a Buy consensus rating as of May 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CVRx (CVRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.